{"id":"bms-708163","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1090771","moleculeType":"Small molecule","molecularWeight":"520.89"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting BACE1, BMS-708163 reduces the cleavage of amyloid precursor protein (APP) into amyloid-beta peptides, potentially slowing the progression of Alzheimer's disease.","oneSentence":"BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:50:01.530Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00890890","phase":"PHASE2","title":"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Alzheimer's Disease","enrollment":263},{"nctId":"NCT00810147","phase":"PHASE2","title":"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02","conditions":"Alzheimer's Disease","enrollment":209},{"nctId":"NCT01454115","phase":"PHASE1","title":"Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Alzheimer's Disease","enrollment":116},{"nctId":"NCT01079819","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-04","conditions":"Alzheimer's Disease","enrollment":32},{"nctId":"NCT01002079","phase":"PHASE1","title":"Drug-Drug Interaction Study With Rifampin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT00860275","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-04","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT01039194","phase":"PHASE1","title":"Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":"Alzheimer Disease","enrollment":18},{"nctId":"NCT01042314","phase":"PHASE1","title":"Drug-Drug Interaction Study With Aricept® (Donepezil)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":"Alzheimer Disease","enrollment":18},{"nctId":"NCT01057030","phase":"PHASE1","title":"Multiple Dose Japanese Bridging Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-03","conditions":"Alzheimer Disease","enrollment":22},{"nctId":"NCT00828646","phase":"PHASE1","title":"Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-10","conditions":"Healthy","enrollment":32},{"nctId":"NCT00901498","phase":"PHASE1","title":"Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Alzheimer's Disease, Healthy","enrollment":36},{"nctId":"NCT00979316","phase":"PHASE1","title":"Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-09","conditions":"Alzheimer Disease","enrollment":62},{"nctId":"NCT00726726","phase":"PHASE1","title":"Drug Interaction Study With a Potential Alzheimer's Disease Compound","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Alzheimer Disease","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(GAMMA SECRETASE inhibitor)"],"phase":"phase_2","status":"active","brandName":"BMS-708163","genericName":"BMS-708163","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}